Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 5/20 | 0.50 |
| ▸ | CES2 | O00748 | 3/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | GMNN | O75496 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | MGAM | O43451 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SI | P14410 | 1/20 | 0.44 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 4/20 | 0.43 |
| ▸ | PLA2G6 | O60733 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11328942 | 0.94 | CES2 (0.57) | CES1CES2CYP2C9HSD17B10GMNN | |
| SCHEMBL17785152 | 0.92 | CES2 (0.60) | CES1CES2CYP2C9HSD17B10GMNN | |
| SCHEMBL10502981 | 0.92 | CES2 (0.60) | CES1CES2CYP2C9HSD17B10GMNN | |
| SCHEMBL20819698 | 0.92 | CES2 (0.60) | CES1CES2CYP2C9HSD17B10GMNN | |
| SCHEMBL20483653 | 0.89 | CES1 (0.52) | CES1CES2CYP2C9HSD17B10GMNN | |
| SCHEMBL22710170 | 0.87 | GAA (0.48) | CES2CYP2C9HSD17B10ALDH1A1TSHR | |
| SCHEMBL20841661 | 0.87 | MGAM (0.52) | CYP2C9HSD17B10POLBALDH1A1TSHR | |
| SCHEMBL11451516 | 0.86 | HSD17B10 (0.50) | CES1CES2CYP2C9HSD17B10GMNN | |
| SCHEMBL14643394 | 0.86 | CYP1A2 (0.53) | HSD17B10POLBALDH1A1TSHRMGAM | |
| SCHEMBL7527314 | 0.85 | MGAM (0.50) | CYP2C9HSD17B10POLBALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11693310-B2 | Blue curable resin composition, blue color filter, and display device including same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-07-04 | — | — | US | disclosed |
| EP-2797870-B1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING 1-[1-PHENYL-CYCLOBUTYL]ISOBUTYLAMINE DERIVATIVES | REVIVA PHARMACEUTICALS INC (US) | 2019-02-20 | — | — | EP | disclosed |
| US-10035761-B2 | Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives | Revivia Pharmaceuticals, Inc. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20180127362-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PHENYLCYCLOALKYLMETHYLAMINE DERIVATIVES | REVIVA PHARMACEUTICALS INC (US) | 2018-05-10 | — | — | US | disclosed |
| US-9695116-B2 | Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives | REVIVA PHARMACEUTICALS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| CN-104039753-B | The compositions of phenylcycloalkyl methylamine derivative, synthesis and using method | 雷维瓦药品公司 | 2016-09-14 | — | — | CN | disclosed |
| US-20160115121-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PHENYLCYCLOALKYLMETHYLAMINE DERIVATIVES | REVIVA PHARMACEUTICALS INC (US) | 2016-04-28 | — | — | US | disclosed |
| US-9238625-B2 | Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives | REVIVA PHARMACEUTICALS, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| US-9051397-B2 | Oxime ester | BASF SE (DE) | 2015-06-09 | — | — | US | disclosed |
| US-9051397-B2 | Oxime ester | BASF SE (DE) | 2015-06-09 | — | — | US | disclosed |
| EP-2797870-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PHENYLCYCLOALKYLMETHYLAMINE DERIVATIVES | Reviva Pharmaceuticals, Inc. (US) | 2014-11-05 | — | — | EP | disclosed |
| EP-2625166-B1 | OXIME ESTER DERIVATIVES OF BENZOCARBAZOLE COMPOUNDS AND THEIR USE AS PHOTOINITIATORS IN PHOTOPOLYMERIZABLE COMPOSITIONS | BASF SE (DE) | 2014-09-24 | — | — | EP | disclosed |
| CN-104039753-A | Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives | REVIVA PHARMACEUTICALS INC | 2014-09-10 | — | — | CN | disclosed |
| US-20140024679-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PHENYLCYCLOALKYLMETHYLAMINE DERIVATIVES | REVIVA PHARMACEUTICALS, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-20130188270-A1 | OXIME ESTER | BASF SE (DE) | 2013-07-25 | — | — | US | disclosed |
| US-20130188270-A1 | OXIME ESTER | BASF SE (DE) | 2013-07-25 | — | — | US | disclosed |
| WO-2013102195-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PHENYLCYCLOALKYLMETHYLAMINE DERIVATIVES | REVIVA PHARMACEUTICALS, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
| WO-2012045736-A1 | OXIME ESTER DERIVATIVES OF BENZOCARBAZOLE COMPOUNDS AND THEIR USE AS PHOTOINITIATORS IN PHOTOPOLYMERIZABLE COMPOSITIONS | BASF SE (DE) | 2012-04-12 | — | — | WO | disclosed |
| US-7214465-B2 | Positive photosensitive composition | FUJIFILM CORPORATION (JP) | 2007-05-08 | — | — | US | disclosed |
| US-4317783-A | 1-Oxo-3-methyl-2-butene phosphonic acid esters | BAYER AKTIENGESELLSCHAFT (DE) | 1982-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024679-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PHENYLCYCLOALKYLMETHYLAMINE DERIVATIVES | PNMT, HTR6, COMT | CES1 158/4885CES2 42/4885CYP2C9 77/4885 |
| US-10035761-B2 | Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives | PNMT, HTR6, COMT | CES1 158/4885CES2 42/4885CYP2C9 77/4885 |
| US-20130188270-A1 | OXIME ESTER | CBR3, CBR1, COX15 | CES1 840/4885CES2 538/4885CYP2C9 56/4885 |
| US-20160115121-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PHENYLCYCLOALKYLMETHYLAMINE DERIVATIVES | PNMT, HTR6, COMT | CES1 158/4885CES2 42/4885CYP2C9 77/4885 |
| US-20180127362-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PHENYLCYCLOALKYLMETHYLAMINE DERIVATIVES | PNMT, HTR6, COMT | CES1 158/4885CES2 42/4885CYP2C9 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.